GlassScriptPhysician profile
Sopan Lahewala
NPI 1376910612
$4,311.60
in general payments reported to CMS, 2019-2025
20 companies · $2,090 in 2025
The $2,090 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $122 · 2021: $116 · 2022: $111 · 2023: $481 · 2024: $1,246 · 2025: $2,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622 · Education: $1,117 · Travel and Lodging: $678 · Grant: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.12 |
| Education | $1,117.06 |
| Travel and Lodging | $677.61 |
| Grant | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,727.55 | 2023-2025 | General - Therapies, General - Vascular Access, General - Catheter |
| Medtronic, INC. | $595.59 | 2024-2025 | Resolute Onyx, Onyx Frontier, Corevalve Evolut R |
| Abbott Laboratories | $521.15 | 2022-2025 | Aveir, Ensite, Cardiomems |
| Shockwave Medical, INC | $477.57 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Chiesi USA, INC. | $226.30 | 2023-2025 | Kengreal, Cleviprex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.85 | 2020-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $124.88 | 2019-2025 | |
| Pfizer INC. | $76.90 | 2019-2024 | |
| Abiomed | $65.25 | 2022-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $59.94 | 2019-2021 | |
| Amgen INC. | $50.43 | 2023-2024 | Repatha |
| Lantheus Medical Imaging, INC. | $44.55 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $44.13 | 2021-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.37 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $32.09 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $22.06 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.41 | 2021 | |
| Merck Sharp & Dohme LLC | $18.34 | 2019 | |
| Karyopharm Therapeutics INC. | $18.09 | 2020 | |
| Gilead Sciences, INC. | $16.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sopan Lahewala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.